Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.

Search results

Showing results for

Enquire now

Join the BioEscalator mailing list

Similar stories

Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151

PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data

Enara Bio to unveil first-in-class DARKFOX-targeting bispecific T cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential for solid tumour immunotherapy

Explore

Information